Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Teleflex IncorporatedNYSE: TFX

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses declines year over year

Q2 FY2026 operating expenses of $271.45M fell 1.6% year over year, ahead of the -4.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.

Context

  • Operating expenses amounted to 43.4% of revenue in FY2025, down 7.5 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.6% holds above the trailing-twelve-month pace of -4.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$271.45M-5.5% QoQ
Last fiscal yearDec 2025
$864.95M-44.3% YoY
LTMJun 2026
$1.31B-4.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year-44.3%——
3-year CAGR-5.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
864.95M USD
Year-over-year change
-44.3%
4-year CAGR
-1.6%

Operating Expenses vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.4% is the 10th highest of 11, against a peer median of +14.8%.
  • Operating expenses amounts to 50.4% of revenue for TFX, versus a peer median of 61.3%.
TFX Competitors
Operating Expenses for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$2.66B USD-1.5%+8.5%50.1%
ALKSAlkermes plcLTM Sep 2026$1.39B USD+46.2%+4.5%79.2%
TFXTeleflex IncorporatedLTM Jun 2026$1.31B USD-4.4%-5.7%50.4%
PCVXVaxcyte, Inc.LTM Jun 2026$1.16B USD+65.4%+58.4%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.16B USD+58.1%+38.7%256.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$712.31M USD-28.4%-10.0%70.6%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$578.71M USD+7.5%+8.6%35.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$549.98M USD+56.6%+21.1%61.3%
CRSPCRISPR Therapeutics AGLTM Sep 2026$389.17M USD+13.2%-15.6%1546.0%
KRYSKrystal Biotech, Inc.LTM Jun 2026$213.23M USD+8.7%+11.1%48.4%
STVNStevanato Group S.p.A.LTM Jun 2026€159.84M EUR+16.5%+5.0%13.1%
Peer median (excluding TFX) —+14.8%+8.5%61.3%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.